Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)
Bullboard Posts
User Avatar Image
(3)
•••
Comment by themagicboxon Jan 30, 2020 4:28pm
169 Views
Post# 30621988

RE:RE:RE:RE:RE:Confusion

RE:RE:RE:RE:RE:ConfusionThats an interesting point but it is not true for a few reasons:

1- they calculate the number of candidates required based on the statistical significance required to demonstrate efficacy for partners. This will demonstrate both reliability and derisk it.
2- they are on record from IR (on the discord group) that will enrol 360 AND complete 360 patients
3-the sites/clinics who are recruiting are still doing so until they meet their quota. 

This is why they gave themselves enough wiggle room by saying Q1 2020. 

Daydream2 wrote: Keep in mind that there is the possibility that the company can stop the trial recruitment at any time if they feel that they have sufficient candidates (360 candidates is not an absolute number to be obtained) and recruitment is stalled. For example, I would say that 350 candidates results has as much weight as 360. Than, this could lead to an announcement that the trial is over and results are tabulated. No quite the same as an announcement that the last candidate has been recruited.



Bullboard Posts
Dealroom for high-potential pre-IPO opportunities